TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03440125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cayenne Pepper topical
Description: 20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cayenne Pepper topical
Description: 20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cayenne Pepper topical
Description: 20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Electrical stimulation 10min 60Hz biphasic rectangular neuromuscular electrical Stimulation (NMES)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage
Description: 10 minutes of classical massage of low back pain area.
Study: NCT00006079

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive oral placebo daily for 28 days.
Study: NCT00777309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: 360 mg administered twice daily until disease progression, unacceptable toxicity or other discontinuation criterion is met
Study: NCT00256516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCEP diet
Study: NCT00597493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib and Temozolomide
Description: Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).
Study: NCT03846557

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Implantation of the Acurate Neo Transcatheter Heart Valve
Study: NCT01854268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Healthy adults who receive capsaicin
Description: Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
Study: NCT00978874

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 EF5
Study: NCT03545542

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Initial fecal microbiome
Description: Stool sampling for fecal microbiome analysis by 16S rDNA pyrosequencing. Neuroblastoma group and Control group.
Study: NCT02836899

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the placebo group. Nitrogen will be added instead of nitric oxide.
Study: NCT00777309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo is provided as a capsule
Study: NCT01867086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™ Vaccine
Description: Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatinum
Description: Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatinum and Taxol
Description: Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
Study: NCT03792568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALK Inhibitor
Description: Any ALK inhibitor like crizotinib, alectinib and so on.
Study: NCT02180841

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy Protein Powder (25g/d)
Description: Participants will consume 25g soy protein powder daily for a 6 week treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Powder (25g/d)
Description: Participants will consume 25g soy protein powder daily for a 6 week treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Powder (25g/d)
Description: Participants will consume 25g soy protein powder daily for a 6 week treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.
Study: NCT03545542

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial fecal microbiome
Description: Stool sampling for fecal microbiome analysis by 16S rDNA pyrosequencing. Neuroblastoma group and Control group.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Initial fecal volatile organic compounds
Description: Volatile organic compound analysis of stool samples by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
Study: NCT01272609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol + LCP
Description: Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCP
Description: Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.
Study: NCT01984008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picosulfate sodium, magnesium oxide, citric acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picosulfate sodium, magnesium oxide, citric acid
Study: NCT00813085

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic disease management decision support
Description: A Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS)
Study: NCT03343041

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low-carbohydrate nutrition
Description: low-carbohydrate enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard enteral nutrition
Description: standard enteral nutrition
Study: NCT02180841

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy Protein Powder (50g/d)
Description: Participants will consume 50g soy protein powder daily for a 6 week treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Powder (50g/d)
Description: Participants will consume 50g soy protein powder daily for a 6 week treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Powder (50g/d)
Description: Participants will consume 50g soy protein powder daily for a 6 week treatment period.
Study: NCT04541511

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minutes walking test on a corridor
Description: 6-minutes walking test on a corridor : patient will be asked to achieve the longest possible distance without running. He/she will be allowed to take breaks if he/she feels the need to do so.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minutes walking test on a treadmill
Description: 6-minutes walking test on a treadmill : patient will be asked to achieve the longest possible distance without running on the treadmill. He/she will be allowed to take breaks if he/she feels the need to do so.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minutes walking test on a treadmill
Description: 6-minutes walking test on a treadmill : patient will be asked to achieve the longest possible distance without running on the treadmill. He/she will be allowed to take breaks if he/she feels the need to do so.
Study: NCT02504307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus Eluting Stent Inspiron
Description: Angioplasty with Sirolimus Eluting Stent Inspiron implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Stent
Description: Angioplasty with Bare Metal Stent Cronus implantation
Study: NCT00732108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 50mg orally for 2 weeks, then 100mg orally for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactulose placebo pill
Description: 1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
Study: NCT03545542

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial fecal volatile organic compounds
Description: Volatile organic compound analysis of stool samples by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Initial breath volatile organic compounds
Description: Breath sampling for organic compound analysis by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial breath volatile organic compounds
Description: Breath sampling for organic compound analysis by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbiome under chemotherapy
Description: Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to Société Internationale d´Onclogie Pediatrique Neuroblastoma Group (SIOPEN) guidelines

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal volatile organic compounds under chemotherapy
Description: Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath volatile organic compounds under chemotherapy
Description: Breath sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Final microbiome
Description: Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Final fecal volatile organic compounds
Description: Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Final breath volatile organic compounds
Description: Breath sampling 3 weeks after completion of chemotherapy Neuroblastoma group
Study: NCT00802893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6R-BH4
Description: 6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo given BID for entire length of study
Study: NCT02868229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR-001

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01113580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL's 2010/2011 Formulation of Enzira® Vaccine
Description: 45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL's 2010/2011 Formulation of Enzira® Vaccine
Description: 45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
Study: NCT03527524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise with ball
Description: exercise with ball

Intervention type: OTHER
Group type: OTHER
Intervention: exercise without ball
Description: exercise without ball
Study: NCT02961946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.
Study: NCT01778803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defactinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT03094442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: An 8 mg dose of Dexamethasone is administered at the time of induction of general anesthesia. The medication is provided by the pharmacy in a blinded syringe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
Study: NCT03853941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Theory-based communication training programme delivered to healthcare professionals
Study: NCT02488733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LSG
Description: In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines

Intervention type: DRUG
Group type: OTHER
Intervention: CMT
Description: CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMT
Description: CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
Study: NCT01985256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511
Description: All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antifungal 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after the second administration of Toca 511,patients will begin 7-day course of oral 5-FC, repeated every 4 weeks for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC
Study: NCT02834559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil and low molecular weight heparin
Description: Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
Study: NCT05737927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 16 g coated beads (47% w/w)
Description: After an overnight fasting of about 10 hours, the subjects were administered 16 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Study: NCT02961946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.
Study: NCT00759408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: 6-120 µg/min
Study: NCT05737927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 12 g uncoated beads
Description: After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 12 g coated beads (60% w/w)
Description: After an overnight fasting of about 10 hours, the subjects were administered the coated Glucose beads formulation (60 % w/w glucose/bead; 12 g glucose) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 12 g coated beads (47% w/w)
Description: After an overnight fasting of at least 10 hours, the subjects were administered the new developed Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. Treatment duration: Day 1 - Day 4
Study: NCT02936284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Enhancement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Play Date
Study: NCT01189643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
Description: Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
Study: NCT02406404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive spirometer training
Description: The incentive spirometer, a device that can help improve breathing and strengthen inspiratory muscles. First, the subjects exhaled normally, then placed the mouthpiece in their mouth and sealed their lips around the mouthpiece. Then they inhaled slowly and deeply with their lips sealed tightly on the mouthpiece. After they inhaled as deeply as possible, held their breath for at least 3 seconds, and then removed the mouthpiece from their mouth and breathed out normally. Subjects repeated this technique 10-15 times. When they finished 10-15 exercises, they took a deep breath and coughed. The training was performed ten sessions daily, for 4 weeks.
Study: NCT00590109

Intervention type: OTHER
Intervention: Blood test
Description: subjects will provide one 8ml blood sample drawn into one ACD tube and 16ml of blood drawn into two EDTA (purple top) tubes.

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire encompassing medical, environmental exposure, and reproductive history.
Study: NCT02300519

Intervention type: OTHER
Intervention: blood sampling
Description: Samplings will be taken on 4 citrated S-monovette tubes, 3 citrated tubes and 1 EDTA tube, namely 36.5 ml for each volunteer